Fortrea (NASDAQ:FTRE – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
Institutional and Insider Ownership
7.5% of Aclarion shares are held by institutional investors. 0.1% of Fortrea shares are held by insiders. Comparatively, 22.3% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Fortrea and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortrea | -4.11% | 4.76% | 1.87% |
| Aclarion | -10,246.33% | -2,554.98% | -251.78% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortrea | 1 | 7 | 3 | 1 | 2.33 |
| Aclarion | 0 | 0 | 1 | 0 | 3.00 |
Fortrea presently has a consensus price target of $27.70, suggesting a potential upside of 24.33%. Aclarion has a consensus price target of $1.60, suggesting a potential upside of 620.07%. Given Aclarion’s stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Fortrea.
Earnings & Valuation
This table compares Fortrea and Aclarion’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fortrea | $3.01 billion | 0.66 | -$3.40 million | ($1.39) | -16.03 |
| Aclarion | $60,048.00 | 30.35 | -$4.91 million | N/A | N/A |
Fortrea has higher revenue and earnings than Aclarion.
Summary
Fortrea beats Aclarion on 7 of the 12 factors compared between the two stocks.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
